CD274 and neoplasm: Assessment by immunohistochemistry staining of PD‐L1 expression is a logical biomarker to filter populations with favourable prognosis to anti‐PD‐1 or anti‐PD‐L1 therapies.5 Besides the PD‐L1 expression, patients with higher expression of T‐effector interferon‐γ signature,6, 7 expanded T cell repertoire and higher tumour‐infiltrating lymphocyte density were seen with improved disease control.8, 9 All of the above characteristics were considered because of the immunogenicity of TME.